Skip to main content
Bart Scott, MD, Oncology, Seattle, WA, UW Medicine/University of Washington Medical Center

BartLeeScottMD

Oncology • Seattle, WA

Hematologic Oncology

Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Scott is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Scott's full profile

Already have an account?

Education & Training

  • University of Washington
    University of WashingtonFellowship, Medical Oncology, 1999 - 2000
  • University of South Alabama College of Medicine
    University of South Alabama College of MedicineClass of 1996

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 1999 - 2024
  • MD State Medical License
    MD State Medical License 2000 - 2001

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...  
    Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
  • Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft‐Versus‐Host Disease: Analysis of BMT CTN‐0201 and ‐0901 Samples  
    Armin Rashidi, Edmund K Waller, Bharat Thyagarajan, Claudio Anasetti, Daniel J Weisdorf, Bart L Scott, Bruce R Blazar, British Journal of Haematology

Abstracts/Posters

  • Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
    Bart L. Scott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
    Bart L. Scott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden
    Bart L. Scott, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Ch... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Successes in Bone Marrow Failures - 2011 ASH Satellite 
    Cleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, San Diego, California - 12/9/2011

Press Mentions

  • Fred Hutch at ASCO: New Insights on Financial Toxicity, Combination Therapies for Cancer and the Need for Targeted Breast Cancer Therapies in Uganda
    Fred Hutch at ASCO: New Insights on Financial Toxicity, Combination Therapies for Cancer and the Need for Targeted Breast Cancer Therapies in UgandaMay 26th, 2023
  • Column: We Pray for Damar Hamlin — and Then Settle Back in for More Football
    Column: We Pray for Damar Hamlin — and Then Settle Back in for More FootballJanuary 8th, 2023
  • Myeloablative Therapy Prevails in AML Transplant Study
    Myeloablative Therapy Prevails in AML Transplant StudyFebruary 21st, 2020
  • Join now to see all

Grant Support

  • Improving Allogenic Transplant Outcomes In Myeloid MalignanciesNational Heart, Lung, And Blood Institute2007–2011

Hospital Affiliations

Dr. Bart Scott, Dr. Bart Scott, MD, Dr. B Scott, Dr. Bart Lee Scott